Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...
SB Nation on MSN
Reds trade interest in Astros CF Jake Meyers raises questions
While the most fun nuggets of that conversation revolve around the idea that the Reds might have a chance to land the ...
JLL, a leading global commercial real estate and investment management company, on Tuesday announced it has signed a lease ...
Data from Phase 2 Trials Underscore Cardioprotective Potential GRAND RAPIDS, Mich., Dec. 9, 2025 /PRNewswire/ -- Cirius Therapeutics, ...
The best PFS results we’ve ever seen in relapsed, refractory myeloma.”The combination of teclistamab (Tecvayli, Janssen) plus ...
Daniel Ives You can reverse the age of cells all the way down to zero in just a few weeks. So you can actually take a ...
XmAb819 demonstrated a manageable safety profile with primarily grade 1 or 2 cytokine release syndrome and no neurotoxicity in ccRCC patients. The trial involved 69 patients, with a 25% objective ...
ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...
IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 December 9, 2025 12:30 PM ESTCompany ParticipantsShaun Bagai - ...
Clinician Perspectives on Holistic Management of PKP2-Associated Arrhythmogenic Cardiomyopathy December 9, 2025 3:00 ...
RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback